Vitamin D Receptor Antagonists for the Treatment of Asthma

INVENTORS • Hector DeLuca, Rafal Barycki, Moises Rivera-Bermudez, Lori Plum, Margaret Clagett-Dame

WARF: P04081US

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing antagonists of the vitamin D receptor that are useful for treating conditions such as asthma or eczema.

OVERVIEW

Asthma is a major medical problem world-wide, particularly in well-developed countries. The incidence and severity of asthma are increasing – approximately six percent of the population of the United States now has asthma. Experiments have shown that administration of vitamin D makes some asthma symptoms worse, suggesting that vitamin D inhibitors may be useful in the treatment of asthma; however, no true in vivo antagonist of vitamin D is currently known.

THE INVENTION

UW-Madison researchers have identified several antagonists of the vitamin D receptor that are useful for treating asthma and eczema. The antagonists include various 19-nor 2 alkylidene and 2alpha-alkyl analogs of vitamin D. These compounds interfere with binding between vitamin D and its receptor both in vivo and in vitro.

APPLICATIONS

• Treating asthma or eczema
• Treating hypercalcemia, hyperparathyroidism, sarcoidosis or vitamin D intoxication

KEY BENEFITS

• Provides valuable new therapies for conditions such as asthma and eczema
• May be administered through various methods, including topically or as an aerosol using an inhaler or nebulizer
• Effective in humans and a wide variety of animals
ADDITIONAL INFORMATION

Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
Pharmaceuticals & Vitamin D - Immunity & auto-immune

CONTACT INFORMATION

For current licensing status, please contact John Nagel at jnagel@warf.org or 608-960-9848.